PYCR1 and colorectal cancer: Furthermore, silencing of PYCR1 reduces the cell growth, drug resistance, and epithelial-mesenchymal transition (EMT) by inactivating the p38 mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways in colorectal cancer cells [27].